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Allogeneic hematopoietic stem cell transplantation (HSCT) recipients are at high risk for developing Clos-
tridium difﬁcile infection (CDI). We studied the incidence, risk factors, NAP1/027 prevalence, and clinical
outcomes, including acute lower gastrointestinal graft-versus-host disease (GI GVHD), associated with early
CDI in this population. A retrospective review was conducted of patients who underwent allogeneic HSCT at
Memorial Sloan Kettering Cancer Center from January 1, 2005 to September 30, 2010. Early CDI was deﬁned as
infection occurring from day 10 to day þ40 from stem cell infusion. Among 793 patients who received
allogeneic HSCTs, early CDI occurred in 11.9%; 56% cases were between day 5 and day þ5. Overall incidence
was 25.2 cases/10,000 at-risk days. There was a high prevalence of NAP1/027 strains during peak incidence
(61% in 2008). NAP1/027 was the most common strain in both adult and pediatric cases (24% and 23%,
respectively). CDI was clinically mild, including those due to NAP1/027. Metronidazole was the primary
treatment for 91 of 94 patients, 7 of 8 cases refractory to metronidazole had no response to vancomycin, and
none was due to NAP1/027. Relapse of CDI was common (31%). The cumulative incidence of GI GVHD in
patients with and without early CDI was 6.8% and 8%, respectively (P ¼ .5). Most cases of CDI occurred during
conditioning or immediately after transplant. Despite high prevalence of NAP1/027, we found only mild
disease. Most patients were treated successfully with metronidazole, irrespective of NAP1/027 status. There
was no signiﬁcant association between early CDI and subsequent development of GI GVHD. This study
demonstrates the high incidence of CDI early after allogeneic HSCT with wide diversity among infecting
strains. Despite the high prevalence of NAP1/027, the disease is mild but relapses are common. No association
was found between CDI and subsequent development of GI GVHD.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Patients undergoing hematopoietic stem cell trans-
plantation (HSCT) are particularly at risk for Clostridium
difﬁcile infection (CDI) because of the extended length of stay
for transplant, frequent antibiotic use, and an immunocom-
promised state. C. difﬁcile rates as high as 12.5% to 27% have
been described in allogeneic HSCT recipients, a risk 15 to 20
times greater than other hospitalized patients [1-6],
including solid organ transplant recipients.edgments on page 1632.
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14.06.025Despite the rising incidence of CDI since the emergence of
the NAP1/027 strain, the prevalence and impact of infection
with this particular strain among allogeneic HSCT recipients
has never been examined [7,8]. Although the frequency of
CDI is much higher among allogeneic HSCT recipients when
compared with autologous stem cell and solid organ trans-
plantation recipients, the disease is reported to be mild in
allogeneic HSCT recipients [2,9-12]. Despite this, immuno-
compromising conditions have been associated with severe
CDI. As a consequence, some experts recommend vancomy-
cin as ﬁrst-line therapy for CDI because of the inability to
accurately apply clinical scoring systems that measure
severity of CDI in this population [13,14]. CDI has also been
implicated in the development of acute gastrointestinal
graft-versus-host disease (GI GVHD), postulated to beTransplantation.
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proinﬂammatory cytokines. However, no conclusive evi-
dence has supported this hypothesis [1,12,15].
We examined the incidence, molecular epidemiology, and
clinical characteristics of early CDI, especially in relation to
occurrence of the NAP1/027 strain. We also explored the
potential relationship between early CDI and subsequent
development of GVHD, with a focus on grade II or higher
acute lower GI GVHD, in a large cohort of allogeneic HSCT
recipients. The study population included patients that had
received conventional T celledepleted and cord blood
allografts.
METHODS
Study Design and Patient Population
This is a retrospective review of 793 adult and pediatric patients who
underwent allogeneic HSCT for hematologic malignancies at Memorial
Sloan Kettering Cancer Center (MSKCC) from January 1, 2005 until
September 30, 2010. During this time, MSKCC was a 432-bed tertiary care
facility in New York City with 19,000 annual admissions and 140,000 patient
days. The adult bone marrow transplant unit at MSKCC is composed of a
29-bed unit, whereas the pediatric inpatient unit has 39 beds. All allogeneic
HSCT patients are admitted to a private room and routinely placed under
protective isolation (mask and gloves).
All demographic, clinical, and laboratory information were obtained
from the institutional Clinical Research Database. Additional information
not available in this database was obtained by MD chart review. The MSKCC
Institutional Review Board reviewed the study and granted a HIPAA waiver
of authorization.
Antibacterial Prophylaxis
Patients received antibacterial prophylaxis starting from day 2 of
allogeneic HSCT until development of febrile neutropenia, overt infection, or
engraftment, whichever occurred ﬁrst. The choice of agent was levoﬂoxacin
for patients receiving a nonmyeloablative conditioning regimen regardless
of stem cell source. Ciproﬂoxacin was used for cord blood recipients who
underwent myeloablative or reduced-intensity conditioning. Vancomycin
prophylaxis was used for recipients of peripheral blood or bone marrow
allografts who received a myeloablative or reduced-intensity conditioning
regimen. Engraftment was deﬁned as the ﬁrst of 3 consecutive days with an
absolute neutrophil count>500 cells/mL. Fever was deﬁned as a temperature
38.0C.
Graft-versus-Host Disease
GVHD was monitored and managed as per MSKCC guidelines and was
graded according to the International Bone Marrow Transplant Registry
classiﬁcation [16]. Acute lower GI GVHD was deﬁned as GVHD that was
diagnosed within the ﬁrst 100 days after transplant.
Clostridium difﬁcile Infection
Case deﬁnition
A case of CDI was deﬁned by clinical history compatible with CDI and a
positive test. “Early” CDI was an infection that occurred from day 10 until
day þ40 of transplant. This timeline was derived from the median length of
stay for ﬁrst transplants during the study period. Complicated CDI was
deﬁned by severe disease characterized by any of the following: systemic
sepsis, intensive care unit admission, endoscopic evidence of pseudomem-
branous colitis, or toxic megacolon.
Diagnostic methods
From January 2005 until September 2008, diagnosis of CDI at MSKCC
was performed by the cytotoxin neutralization assay. After September 2008,
a 2-step testing algorithm was implemented that included a ﬁrst-step
glutamate dehydrogenase assay followed by the cytotoxin neutralization
assay for all glutamate dehydrogenaseepositive samples. C. difﬁcile isolates
were routinely stored for typing only after January 2008. PCR ribotyping and
multilocus sequence typing (MLST) of isolates was performed as previously
described [17,18].
Treatment for CDI
First-line treatment was metronidazole 500 mg p.o. (or i.v. for patients
unable to tolerate oral medications) every 8 hours for a total of 14 days or
discontinuation of broad-spectrum antibiotics, whichever was longer.
Second-line treatment was oral vancomycin 125 mg p.o. 4 times daily at the
discretion of the treating physician.Statistical Analysis
Incidence rates were calculated by using the number of events divided
by the total number of patient-days at risk. All second transplants were
removed from the numerator and denominator when calculating incidence.
Categorical variables were compared using the chi-square test, and
continuous variables were compared using the Mann-Whitney rank sum
test for the baseline characteristics of early CDI. Simple logistic regression
was used for the univariate analysis of risk factors of early CDI. Multiple
logistic regression was used for multivariate analysis of risk factors of early
CDI among adult patients.
Time-to-event analyses were conducted by Kaplan-Meier methods and
log-rank test. Competing events for developing GVHD included patient
death, relapse, and second transplant. Patient-days at risk for acute lower GI
GVHDwere fromday 0 of transplant until the development of acute GVHD of
the lower GI tract (stage  2), day þ100 of transplant, second transplant, or
death, whichever occurred ﬁrst. P < .05 was considered to be statistically
signiﬁcant. All statistical analysis was performed using SAS version 9.2 (SAS
Institute, Cary, NC).RESULTS
A total of 793 allogeneic HSCTs were performed during
the study period, comprising 598 adult patients and 195
pediatric patients. Overall, 169 patients (21.3%) had at least 1
episode of CDI in the ﬁrst year after transplant. Early CDI
occurred in 94 transplant recipients (11.9%), including 25
patients younger than 21 years. Overall, the incidence of
early CDI was 25.2 cases per 10,000 patient-days at risk. The
highest percentage of cases were observed in the years 2007
and 2008 (14.3 and 16.3%, respectively) and declined sub-
sequently to 9.1% in 2010 (P ¼ .38). No outbreaks were
reported during the study period (Figure 1).C. difﬁcile Characteristics and Outcome
Ninety-four patients had early CDI, and 56% of infections
occurred from day 5 to day þ5 (Figure 2). Table 1 shows
the baseline characteristics of the study cohort, and
Supplementary Table 1 shows clinical characteristics of pa-
tients with early CDI. Diarrhea was mild (grade 1) in most
cases (76.1%). Forty-four percent of patients were neu-
tropenic, and none developed acute renal failure at the time
of CDI. Fourteen patients had imaging with abdominal x-ray
series or computed tomographic scanning; 3 among these
had evidence of colitis and none had ileus, toxic megacolon,
or evidence of perforation. There were no deaths attributed
to CDI.
Most patients received metronidazole (91/94) at a dose
of 500 mg 3 times daily for 10 to 14 days or until an alter-
nate agent was used. For 8 of 91 patients, treatment was
changed to vancomycin because of persistent diarrhea
(median time to treatment switch, 5.5 days; range, 3 to
8 days). The time of onset of CDI for all but 1 case with
refractory diarrhea was between day 7 and day 0. Seven of
these patients had persistent diarrhea despite changing to
vancomycin, and antimotility agents were eventually used
for symptom relief. In 4 of 7 cases, retesting for CDI was
done before initiating antimotility agents and was negative
in all cases. For 1 patient, diarrhea resolved after changing
to vancomycin without concomitant use of antimotility
agents. Molecular typing was done on isolates retrieved
from 7 of 8 patients; none was infected with the NAP1/027
strain.
Concomitant antibacterial agents for fever and neu-
tropenia prophylaxis or management of concurrent infection
were used in 89% of patients during CDI treatment (Table 2).
Twenty-nine patients (31%) had relapse of CDI. The median
time to relapse was 79 days. Nine patients (9.6%) had early
relapse within 8 weeks after the index episode.
Figure 1. Rate of early CDI among allogeneic HSCT recipients at MSKCC from January 2005 to September 2010. CYT indicates cytotoxin assay; GDH, glutamate
dehydrogenase assay.
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Isolates from 42 of 58 infections that occurred after
January 2008 were available for analysis by MLST and PCR
ribotyping (Figure 3, Supplementary Figure 1). Storage of
samples was random and not determined by clinical severity
of disease. The overall prevalence of NAP1/027 among the
typed isolates from the study years 2008 to 2010 was 24%.
The highest frequency of infections by NAP1/027 correlated
with the peak incidence of CDI in 2008, when 61% (8/13)
of all typed isolates were NAP1/027. The percentage of
NAP1/027 in the study in 2009 and 2010 were 6.2% and 7.6%,
respectively.
Therewas concordance between theMLST and ribotyping
results; all 10 isolates identiﬁed as 027 in our study were
identiﬁed as ST-1 by the MLST scheme. The 32 non-NAP1
strains were characterized by MLST: the most common
among these was ST-2 (n ¼ 5) followed by ST-3 and -42
(n ¼ 3 each), followed by ST-8, -10, -11, -43, -44, and -58 (2
each) and isolated strains belonging to ST types 4, 16, 34, 41,
46, 54, 103, 123, and 191. Although most NAP1 infectionsFigure 2. Frequency distribution of timing of early CDI cwere detected in the second half of 2008, none of these or
other patients diagnosed with common strains overlapped in
time or space, suggesting that hospital-based transmission
did not occur during the time of transplant (Figure 3).
The 42 typed isolated included 13 of 16 infections (81%)
from pediatric transplant recipients and 29 of 42 infections
(69%) diagnosed from adult transplant recipients during this
time period. NAP1/027 strains accounted for approximately
one fourth of infections in both populations (23% in pediatric
and 24% in adult patients). Univariate analysis did not reveal
any signiﬁcant differences in clinical severity or outcomes
associated with CDI infection due to the NAP1/027 strain
when compared with non-NAP1/027 strains (Table 2). The
only notable ﬁnding was the higher relapse rate among
NAP1/027 infections; however, this did not reach statistical
signiﬁcance.
Relationship Between CDI and Acute Lower GI GVHD
To explore the relationship between early CDI and sub-
sequent development of lower GI GVHD, we examined theases in relation to timing from stem cell infusion.
Table 1
Baseline Characteristics of Patients with and without Early CDI
Characteristic Subcategory Total CDI Non-CDI P
Patients 793 (100) 94 (12) 699 (88)
Sex .88
Male 453 (57) 53 (12) 400 (88)
Female 340 (43) 41 (12) 299 (88)
Age
Mean (range) 39.2 (0-73) 37.9 (.7-69.3) 39.4 (0-73) .59
Adult 585 (74) 67 (71) 518 (74) .56
Pediatric 208 (26) 27 (29) 181 (26)
Source .32
Peripheral blood 581 (73) 64 (68) 517 (74)
Cord blood 114 (15) 14 (15) 100 (14)
Bone marrow 98 (12) 16 (17) 82 (12)
T cell depletion .45
No 383 (48) 42 (45) 341 (49)
Yes 410 (52) 52 (55) 358 (51)
Underlying disease .16
Leukemia 427 (54) 58 (14) 369 (86)
AML 243 (31) 37 (15) 206 (85)
ALL/biphenotypic 138 (17) 20 (14) 118 (86)
CLL 23 (3) 0 (0) 23 (100)
CML/MPD 23 (3) 1 (4) 22 (96)
MDS 91 (11) 12 (13) 79 (87)
NHL 132 (17) 11 (8) 121 (92)
HD 39 (5) 3 (8) 36 (92)
MM 38 (5) 2 (5) 36 (95)
NMHD 66 (8) 8 (12) 58 (88)
Donor .65
MRD 280 (35) 30 (11) 250 (89)
MUD 232 (29) 31 (13) 201 (87)
Mismatched 281 (35) 33 (12) 248 (88)
Conditioning regimen
Myeloablative 495 (62) 65 (13) 430 (87)
Reduced intensity 152 (19) 18 (12) 134 (88)
Nonmyeloablative 146 (18) 11 (8) 135 (92) .18
TBI .07
No 362 (46) 42 (45) 320 (46)
Low dose 124 (16) 8 (8) 116 (16)
Full dose 307 (39) 44 (47) 263 (38)
Values are total number of cases, with percents in parentheses, unless otherwise noted. AML indicates acute myeloid leukemia; ALL, acute lymphoblastic
leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myelogenic leukemia; MPD, myeloproliferative disorders; MDS, myelodysplastic syndrome; NHL,
non-Hodgkin lymphoma; HD, Hodgkin disease; MM, multiple myeloma; NMHD, nonmalignant hematologic disease; MRD, matched related donor; MUD, match
unrelated donor.
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in the ﬁrst 100 days) in patients with and without early CDI.
We only evaluated patients in whom CDI preceded the
development of GI GVHD. Overall, 46 study patients wereTable 2
Clinical Characteristics and Outcomes Associated with NAPI versus Non-
NAP1 Strains
Characteristic Non-NAP1
(n ¼ 32)
NAP1
(n ¼ 10)
P*
Male 20 (62.5) 7 (70.0) 1.0
Median age, yr 39.0 49.5 .77
Pediatric patient 10 (31.3) 3 (30.0) 1.0
Fever 12 (37.5) 2 (20.0) .45
Abdominal pain 8 (25.0) 2 (20.0) 1.0
Diarrhea (more than grade 2)y 6 (18.8) 0 (0) .31
Treatment change 8 (25) 0 (0) .16
Concomitant antibiotics 29 (90.6) 10 (100) 1.0
Relapse 8 (25.0) 5 (50.0) .24
Median time to infection, days .5 1.0 .38
Creatinine > 1.2 2 (6.3) 0 (0) 1.0
ANC < 500 15 (46.9) 4 (40.0) 1.0
Values are total number of cases, with percents in parentheses, unless
otherwise noted. ANC indicates absolute neutrophil count.
* Based on Fisher’s exact test for dichotomous variables and Wilcoxon-
Mann-Whitney for continuous variables.
y More than grade 2 diarrhea ¼ more than 6 stools/day.diagnosed with acute lower Gl GVHD in the ﬁrst 100 days
after transplant, and 4 of these patients had early CDI. The
cumulative incidence of acute lower GI GVHD in patients
with early CDI was 6.8% compared with 8% in patients
without early CDI (P ¼ .5) (Figure 4A). The incidence of acute
lower GI GVHD was highest in patients undergoing con-
ventional transplantation who did not have early CDI,
although the difference did not reach statistical signiﬁcance
(Figure 4B).Transplant Characteristics and Related Risk Factors
We compared the characteristics of 94 cases of early
CDI with the 699 allogeneic HSCT recipients without early
CDI to identify risk factors for early CDI (Table 3). No statis-
tically signiﬁcant associations were found between CDI
and demographic characteristics such as age and sex or
transplant variables such as underlying disease, HLA
matching status, conditioning intensity, use of total body
irradiation (TBI)-containing conditioning regimens, or non-
myeloablative conditioning regimen. The lack of signiﬁcant
association persisted in the adjusted logistic regression
model for CDI. Antibiotic prophylaxis with ﬂuoroquinolones
and vancomycinwas examined, and no associated risk of CDI
was identiﬁed.
Figure 3. Distribution of MLST types from 42 CDIs diagnosed from January 2008 to September 2010. Red triangles represent infections due to the NAP1/027 strain,
and blue diamonds represent non-NAP1 infections. Each horizontal bar connects unique ST types.
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Allogeneic HSCT recipients are among the most suscep-
tible hosts for CDI [1,3,12,15]. Our study demonstrates that
most CDIs occur around the time of conditioning and in the
ﬁrst week after stem cell infusion. We report early CDI rates
over awide peritransplant period (day10 to dayþ40) and a
slightly higher rate than previous studies from major trans-
plant centers that have examined rates of CDI in the ﬁrst
month after allogeneic HSCT (5.6% to 8.35% in the study by
Alonso et al. [1]) and in Europe (6.4% in study by Willems
et al. [6]). Differences in study population, antimicrobial
prophylaxis, and testing practices (eg, varying policies
regarding rejection of formed stools for testing) may account
at least in part for the difference in rates. MSKCC is a referral
center, and about 50% of patients who undergo transplant
have received pretransplant care elsewhere. Often, prior
history of CDI in the pretransplant phase of illness cannot be
ascertained. Most patients (>90%) undergoing allogeneic
HSCT at MSKCC are tested for C. difﬁcile irrespective of stool
consistency, leading to ascertainment bias.Figure 4. (A) Cumulative incidence of acute lower GI GVHD (grade  II) in patients w
(grade  II) in patients with and without early CDI sorted by transplant type. CONVAlthough NAP1 was the most commonly isolated strain
in our cohort, no epidemiologic evidence of patient-to-
patient transmission was found and no outbreaks occurred
during the study period. Overall, 19 ST types were found
among the typed isolates, with NAP 1/027 being the most
common strain. However, the prevalence of this strain var-
ied over time, and overall during the study period, wide
diversity of infecting strains was encountered. This ﬁnding,
along with the timing of infection, suggests that most CDI
seen early after transplant occurs in previously colonized
patients and establishment of colonization likely occurs
before transplant. Prospective studies using PCR for
screening at MSKCC have identiﬁed colonization rates as
high as 39% in this population, with detection mostly early
after transplant. Approximately 70% of patients who
developed early CDI in this cohort were previously colo-
nized with tcdB þ strains of C. difﬁcile [19]. Further evidence
supporting this notion comes from a recent study done at
Karmanos Cancer Center where allogeneic HSCT recipients
were screened for C. difﬁcile upon admission and at weeklyith and without early CDI. (B) Cumulative incidence of acute lower GI GVHD
indicates conventional; TCD, T cell depleted.
Table 3
Risk Factor Analysis of Early CDI: Univariate and Multivariate Analysis for Early CDI
Characteristic Subcategory Univariate Multivariate
Crude OR (95% CI) P AOR (95% CI) P
Sex
Male REF REF
Female .85 (.51-1.44) .55 .69 (.40-1.20) .18
Source
Cord blood REF REF
BM .84 (.22-3.25) .96 .52 (.10-2.71) .93
PBSC .76 (.39-1.49) .62 .31 (.09-1.06) .09
T cell depletion
No REF REF
Yes 1.34 (.81-2.24) 1.09 (.52-2.30) .81
Underlying disease
ALL/Biphenotypic REF REF
AML 1.25 (.56-2.77) .91 1.31 (.55-3.09) .91
CLL NA d NA d
CML/MPD NA d NA d
HD .36 (.07-1.79) .94 .34 (.06-2.07) .93
MDS .87 (.33-2.29) .92 .99 (.33-2.95) .91
MM .33 (.07-1.63) .94 .34 (.06-2.10) .93
NHL .56 (.22-1.43) .93 .52 (.16-1.70) .93
NMHD NA d NA d
Donor
Matched related REF REF
Unrelated Identical 1.19 (.65-2.18) .43 1.20 (.64-2.27) .09
Mismatch .92 (.49-1.74) .55 .47 (.19-1.18) .06
Conditioning regimen
Nonmyeloablative REF REF
Myeloablative 2.39 (1.13-5.06) .04 .51 (.10-2.76) .49
RIC 1.86 (.80-4.32) .56 .54 (.10-2.90) .60
TBI No REF REF
Low* .46 (.20-1.09) .03 .48 (.10-2.38) .32
Full 1.34 (.78-2.30) .02 1.18 (.53-2.63) .33
Antibiotic prophylaxis
None REF REF
Vancomycin only .75 (.31-1.83) .93 .54 (.20-1.45) .61
FQ Only .42 (.12-1.54) .18 .40 (.10-1.62) .34
Vancomycin þ FQ .92 (.38-2.26) .33 .64 (.24-1.74) .84
OR indicates odds ratio; CI, conﬁdence interval; AOR, adjusted odds ratio; REF, reference group; BM, bone marrow; PBSC, peripheral blood stem cell; NA, not
applicable; RIC, reduced-intensity conditioning; FQ, Fluoroquinolone.
* Low TBI < 200 Gy.
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to be colonized with C. difﬁcile on initial screening, and
C. difﬁcile accounted for most patients who developed
infection subsequently. Only 8 of 107 patients who tested
negative on initial screen were later suspected to have
nosocomial acquisition of C. difﬁcile [20].
The NAP1/027 strain ﬁrst appeared in the United States
and North America almost a decade ago [7,21]. Infection due
to this strain has been associatedwith a higher incidence and
severity of infection. The strain is a hypertoxin producer that
has been associated with the increased severity of illness
observed with NAP1/027 infection [22]. The impact of
infection due to this particular strain has not been described
in previous studies of allogeneic HSCT recipients, except in
the study by Willems et al. [6] in which no cases were
attributed to it. At MSKCC, we observed a doubling of the rate
of CDI between the years 2006 and 2007 (Figure 1), without
any substantial change in the number of transplants per-
formed or the testing method for CDI. Although strains from
these study years (2006 and 2007) were not examined by
molecular typing, the NAP1/027 prevalence among tested
strains during peak C. difﬁcile incidence in our cohort was
61%. This suggests that the high rates observed from 2007 to
2009 were likely driven by high prevalence of this strain,
which was endemic at many medical centers across the
United States during these years.The disease observed in out cohort was uniformly mild,
irrespective of the infecting strain type, and no poor out-
comes were associated with NAP1/027 infection except for
higher relapse rates; however, the number of cases were
too small to reach statistical signiﬁcance. Although most
cases of CDI had resolution of diarrhea with metronidazole,
nonresponse was noted in 8 patients in whom treatment
was changed to vancomycin. Diarrhea persisted, however,
and antimotility agents were used for symptom relief in 7
of these patients. Diarrhea in the peritransplant period can
occur because of a variety of factors, and physician
knowledge about the epidemic NAP1/027 strain may have
inﬂuenced decisions regarding treatment change. Among 7
patients in whom treatment failure with metronidazole
was suspected and strain typing could be performed, none
had infection with the NAP1/027 strain. These cases were
not deemed to be metronidazole failures. They occurred
during conditioning or stem cell infusion, and the persis-
tent symptoms were attributed to the regimens rather than
refractory CDI. Vancomycin was used as ﬁrst-line therapy in
only 3 cases. Comparison of vancomycin with metronida-
zole for symptom resolution and relapse therefore could
not be made due to the small number of patients in the
former group. Similar to other studies of allogeneic HSCT
recipients, relapse of CDI was common and occurred in 31%
of patients.
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factor analysis for early CDI suggested that patients with
acute myeloid leukemia and those who received cord blood
grafts had a higher risk of CDI, but the association did not
persist in multivariate analysis. Although studies have
postulated mucosal injury resulting from the conditioning
regimen, especially TBI, as a risk factor for CDI, we did not
ﬁnd a signiﬁcant association even with full-dose TBI [6].
Second, the development of acute lower GI GVHD after CDI
has led some to speculate a causal relationship between the 2
conditions. However, we found the cumulative frequency of
acute lower GI GVHD in our cohort was not signiﬁcantly
different in the group of patients with and without early CDI.
The association, if any, may not have become overt due to the
use of T cell depletion and the lower incidence of GVHD at
our center. No difference was observed when examined by
transplant type, including in persons receiving cord blood
transplants and TBI-containing conditioning regimens,
although only a small number of patients were diagnosed
with acute lower GI GVHD in these groups (Figure 4B). The
reverse association of acute lower GI GVHD as a risk factor for
CDI evaluated in other reports [2,12,15] should be interpreted
cautiously. Testing bias in this population and pitfalls of
current diagnostic methodologies, especially molecular-
based testing, which detects the toxin gene rather than the
toxin, can contribute to overestimates of clinically signiﬁcant
infection.
The limitations of this study are its retrospective design,
the lack of strain typing of all 94 cases of CDI, and the fact that
pretransplant history of CDI could not be ascertained for
approximately half of the patients in our cohort who received
pretransplant care elsewhere. Antibiotics used for treatment
during transplantationwere not evaluated as an independent
variable, because >90% of patients received antibiotic pro-
phylaxis or treatment of infections in the ﬁrst 40 days after
transplant. Diarrhea occurs relatively commonly in the early
transplant period because of the effects of conditioning reg-
imens, and thus the patients are tested for enteric pathogens
frequently. It is possible that some patients who were carriers
of C. difﬁcile had the diarrheal illness ascribed to CDI when in
fact the conditioning regimen caused the symptoms, leading
to an overestimation of rates.
Our ﬁndings are especially relevant because of the
widespread implementation of molecular-based testing
methods by most transplant centers. Recently, PCR-based
screening using serial stool samples from patients undergo-
ing allogeneic HSCT at our center identiﬁed 37 patients with
toxigenic C. difﬁcile, among which only 16 were clinically
suspected to have CDI [19]. When used for diagnosis of CDI,
molecular methods offer many advantages over widely used
enzyme immunoassays and cytotoxin neutralization assays,
including higher sensitivity and rapid turnaround time, and
detection of colonization is much higher with these assays
that detect the toxin gene. With doubling of C. difﬁcile
detection rates reported by many centers after imple-
mentation of PCR [3,23], interpretation of a positive test in
this population will have to be carefully evaluated in pro-
spective studies that use screening strategies and rigorously
implemented clinical scoring systems to overcome the
diagnostic challenge of distinguishing between active infec-
tion and colonization [3].
Notably, this study found very mild CDI disease, in contrast
to the severe infections reported in solid organ transplant
recipients. Even the NAP1/027 strain, which accounted for
most infections in our cohort, was not associated with severeillness in this population, perhaps demonstrating the impor-
tance of host factors in the development of severe disease.
Although conventional C. difﬁcile severity scoring systems are
not applicable in our cohort, metronidazole appears to be safe
and effective in this population, despite widespread use of
concomitant antibacterial agents. The impact of treatment
choice on reducing relapse of C. difﬁcile disease needs to be
formally investigated in prospective studies. Unlike previous
reports, we found no association between early CDI and
subsequent development of acute lower GI GVHD in our
cohort [1,12,15].ACKNOWLEDGMENTS
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